Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Open
-
A Phase 1/2 Study Of FOG-001 In Participants With Locally Advanced Or Metastatic Solid Tumors
Jacksonville, FL
Rochester, MN
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
-
A Phase 1a/1b Study Of The Safety, Pharmacokinetics, And Antitumor Activity Of The Oral Menin Inhibitor Ziftomenib In Combination With Imatinib In Patients With Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.
-
An Open-label, Multicenter, Dose Escalation And Expansion Phase 1/2 Study To Evaluate The Safety, Tolerability And Pharmacokinetics, And Anti-tumor Activity Of GI-102, A CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As A Single Agent And In Combination With Conventional Anti-cancer Drugs, Pembrolizumab Or Trastuzumab Deruxtecan(T-DXd) In Patients With Advanced Or Metastatic Solid Tumors (KEYNOTE-G08)
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study to evaluate the safety and tolerability of GI-102 to define the MTD and/or RP2D.
Contact Us for the Latest Status
-
A Multicenter, Randomized, Phase 3 Study To Assess The Efficacy And Safety Of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard Of Care In Adults With Locally Recurrent, InoperaBLE, Or Metastatic Soft Tissue Sarcomas (INVINCIBLE-3)
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease progression prior to study enrollment following no more than 2 standard therapies, which must have included an anthracycline-based regimen, unless contraindicated, and then a maximum of 1 additional regimen.
-
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade
Scottsdale/Phoenix, AZ
The purpose of this study is to assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
-
A Phase 1/2 Study Of FOG-001 In Participants With Locally Advanced Or Metastatic Solid Tumors
Scottsdale/Phoenix, AZ
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
-
A Phase 1/2 Study of YH001 in Combination With Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to evaluate the safety and tolerability and determine the recommended Phase 2 dose (RP2D) of YH001 when given with envafolimab dosed at 600 mg SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety and tolerability and determine RP2D of YH001 in combination with envafolimab dosed at 600 mg SC every 3 weeks and doxorubicin dosed at 75 mg/m2 every three weeks in patients with advanced or metastatic sarcoma who have not received doxorubicin or checkpoint inhibitors and are refractory to or intolerant to other available therapies.
-
Expanded Access Program Of AMTAGVI That Is Out Of Specification For Commercial Release
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The objective of this expanded access protocol is to provide access to Out Of Specification (OOS) AMTAGVI treatment to patients.
Closed for Enrollment
-
A Phase 3 Randomized, Open-Label, Multicenter Clinical Study Of CGT9486+Sunitinib Vs. Sunitinib In Subjects With Locally Advanced, Unresectable, Or Metastatic Gastrointestinal Stromal Tumors
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to compare CGT9486 in combination with sunitinib to treat gastrointestinal stromal tumors.
-
ADI-PEG 20 Or Placebo Plus Gemcitabine And Docetaxel In Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
-
CMP-001-010: A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma (CMP-001-010)
Scottsdale/Phoenix, AZ
The purpose of this study is to determine confirmed objective response with CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma. It also aims to evaluate the safety and tolerability of CMP-001 administered by intratumoral (IT) injection in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma and to evaluate the effectiveness of CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma.
-
Collection of Sarcoma Tissue Study
Scottsdale/Phoenix, AZ
The goal of this study is to create a comprehensive system of tissue banking of samples from Mayo Clinic Arizona patients with a clinical diagnosis of sarcoma who will or have undergone a surgical procedure to remove the sarcoma. The tissue samples will be used for future research of sarcoma at Mayo Clinic and future research at Mayo Clinic to learn about, prevent, or treat other health problems.
-
Collection of Sarcoma Tissue Study
Scottsdale/Phoenix, AZ
The purpose of this study is to create a comprehensive system of tissue banking of samples from Mayo Clinic Arizona patients with a clinical diagnosis of sarcoma who will or have undergone a surgical procedure to remove the sarcoma.
-
Randomized, Controlled, Open-label, Phase IIb/III Study Of Lurbinectedin In Combination With Doxorubicin Versus Doxorubicin Alone As First-line Treatment In Patients With Metastatic Leiomyosarcoma
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.
.